Navigation Links
Regado Biosciences Awarded Three Grants from the Federal Government to Advance Research of Lead Programs
Date:11/3/2010

This technology is being applied to injectable antithrombotics (including anticoagulants and antiplatelet agents) in the acute and sub-acute care cardiovascular setting, a multi-billion dollar world-wide market in need of drugs with improved safety profiles and a greater degree of therapeutic control.  The products in Regado's pipeline are designed to act as optimized antithrombotics, uniquely concomitantly minimizing the risk of ischemia and bleeding, and, by allowing patient specific tuning of the desired therapeutic effect, providing a safe and unique approach to personalized medicine.

ABOUT REG1, REG2 and REG3  Regado's lead program, the anticoagulant system REG1, consists of two parenteral agents both administered by IV bolus, the first being a potent highly selective Factor IXa inhibitor (pegnivacogin, a.k.a. RB006) and the second being its complementary active control agent (anivamersen, a.k.a. RB007).  Anivamersen can be used to selectively completely or partially reverse the anticoagulant effect of pegnivacogin.  REG1, presently in a phase 2b clinical trial (the RADAR trial), is intended for application in arterial thrombosis applications, initially in Acute Coronary Syndrome patients intended for Percutaneous Coronary Intervention.  A clinical program in Open Heart Surgery [including coronary artery bypass grafting (CABG) and valve repair/replacement] is also under development.  REG2, Regado's second product candidate, consists of a subcutaneously administered depot formulation of pegnivacogin paired with the IV bolus formulation of anivamersen.  REG2 recently completed single escalating dose phase 1 clinical testing (the first successful subcutaneous application of an aptamer in humans) and is planned to be studied in a multiple escalating dose clinical trial in 2011.  It is intended for use in venous thrombosis indications such as venous thromboembolism (VTE) prophylaxis in patients undergoing abdominal s
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Regado Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference in New York City
2. Regado Biosciences to Present at the UBS Global Life Sciences Conference on September 22, 2010 in New York City
3. Regado Biosciences, Inc. Continues to Expand Its Patent Portfolio By Announcing Issuance of a New Patent for Its Product Candidates, the REG1 and REG2 Anticoagulation Systems
4. Regado Biosciences to Present at the BIO International Convention Held in Chicago, Illinois on May 5, 2010
5. Regado Biosciences to Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17, 2009
6. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 16, 2009
7. Regado Biosciences To Present at the 2009 Japan Biopharma Partnering Conference on October 6, 2009
8. Regado Biosciences Announces Allowance in Europe of a Fundamental Patent Broadly Covering Oligonucleotide Modulators to Blood Coagulation Factor Aptamers
9. Regado Biosciences to Present at the BioPharm America 2009 Conference on September 17, 2009
10. Regado Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2009 on September 11, 2009
11. Regado Biosciences to Present at the Rodman & Renshaw Global Investment Conference on September 10, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... -- Lisa Kulik saw fireworks for the first time in ... a groundbreaking retinal implant co-invented by Mark Humayun ... University of Southern California (USC) Eye Institute. ... resident who has retinitis pigmentosa, a degenerative disease ... 2, she became the first person west of the ...
(Date:8/27/2014)... , Aug. 27, 2014 Reportbuyer.com has ... The Graphene Opportunity - A Rational View ... The New Nanotech? A similar amount of ... applications ranging from microelectronics to water treatment, but ... the availability of the Graphene Opportunity Report, authored ...
(Date:8/27/2014)... 2014  ARCH Venture Partners, one of the ... development of seed and early-stage advanced technology companies, ... with more than $400 million in subscriptions. ARCH ... target by more than $150 million. ... and potential of our approach to finding and ...
(Date:8/27/2014)... 2014 After the boom of the ... next beverage craze is going to be the stress ... can use Stress Relief energy pattern which can be ... of a beverage, including minerals, herbs and liquids. Stress ... that power into rapid recovery and helping to adapt ...
Breaking Biology Technology:USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 2USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 3USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 4USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 5The Graphene Opportunity - A Rational View 2The Graphene Opportunity - A Rational View 3The Graphene Opportunity - A Rational View 4Latest ARCH Venture Partners Fund Closes Above $400 Million 2Latest ARCH Venture Partners Fund Closes Above $400 Million 3Stress Relief: 1 Way to De-Stress Your Beverage Formula 2Stress Relief: 1 Way to De-Stress Your Beverage Formula 3Stress Relief: 1 Way to De-Stress Your Beverage Formula 4
... 28 N30 Pharma (N30), a,biopharmaceutical company focused ... regulate nitric oxide bioavailability,announced today that it has ... N30 will use proceeds from this financing ... expand its discovery and preclinical,research in the area ...
... Be Webcast Live On Company,s Website -, TUSTIN, ... ), a clinical stage biopharmaceutical,company developing monoclonal antibodies for ... that senior management will,present at the BIO Investor Forum ... (6:45 pm EDT). The conference will be held at ...
... ITMN ) announced today that it will release ... at 4:00 p.m. Eastern time.,A live conference call and ... time that same day., To access the live ... To access the,webcast, please log on to the company,s ...
Cached Biology Technology:N30 Pharma Announces Financing, Expansion of Board 2Peregrine Pharmaceuticals to Present at BIO Investor Forum 2008 2InterMune to Release Third Quarter 2008 Financial Results on November 6 2
(Date:8/27/2014)... (June, 2014) Outstanding basic research, a growing ... dedication to patient care have earned the Herbert ... Medical Center (CUMC) and NewYork-Presbyterian Hospital an $18 ... National Cancer Institute (NCI). The grant renews the ... Comprehensive Cancer Centers in New York City and ...
(Date:8/27/2014)... factors thought to be associated with outcomes after ... age of the patient, mechanism of injury, nerve ... method, operation technique, and repair materials. However, despite ... peripheral nerve injuries, there is no agreement regarding ... the dose-effect relationship of the predictors has not ...
(Date:8/27/2014)... research finds , Gamblers show the same tendencies ... has shown. , Researchers, led by Dr Elliot Ludvig ... tests that found that both human gamblers and pigeons ... low-value rewards. , Published in Biology Letters , ... important role that memories of previous biggest wins and ...
Breaking Biology News(10 mins):Herbert Irving Comprehensive Cancer Center awarded $18 million grant 2Herbert Irving Comprehensive Cancer Center awarded $18 million grant 3Herbert Irving Comprehensive Cancer Center awarded $18 million grant 4Gamblers are greedy bird-brains, University of Warwick research finds 2
... the body's motor nerve cells grow along proper paths ... inhibiting spinal-cord neurons from regenerating after injury, researchers at ... the researchers found that a component of myelin ?a ... in adult vertebrates ?chemically blocks the ability of nerve ...
... for the first time that bacteria, in addition to ... sparkling wine known as Cava. They report their findings ... Society for Microbiology. , "Bacteria found in Cava samples ... in terms of aroma, flavor, bubble size and bubble ...
... hanging basket style device is at the heart of a plan ... sex drive of a major pest of fruit ... that very same pest. The device allows growers to selectively ... killing other beneficial insects. , The researchers at Warwick HRI, the ...
Cached Biology News:Researchers find molecule that inhibits regrowth of spinal nerve cells 2Researchers find molecule that inhibits regrowth of spinal nerve cells 3After the yeast is gone bacteria continue to develop flavor of sparkling wine 2Hanging baskets of sex and death help fruit growers 2